Dave Ricks told CNBC that ,he estimates 3% to 10% of eligible patients access obesity care in the U.S., He called the room for expansion "dramatic."
Read that again. Between 90% and 97% of eligible Americans are not on the drug yet. That is not a market. That is a threat.
The quarter was already absurd. ,Revenue climbed 39% to $24.4 billion, led by Mounjaro and Zepbound., ,Mounjaro's worldwide revenue rose 65% to $10.72 billion., ,Zepbound rose 49% to $5.35 billion., Analysts expected less. Analysts always expect less. It is their only skill.
Lilly ,raised its 2026 revenue forecast to $91 billion to $92 billion, from ,$85 billion to $87 billion., ,It is the third guidance increase this year., A company that keeps guiding low so it can beat itself. Honest work.
Now the detail nobody wants. ,Volume rose 53% while realized prices fell 15%., Lilly is selling more of the stuff for less each time. Walmart with a pharmacology degree.
The pill is the real comedy. ,Foundayo brought in $184 million. Analysts had forecast about $229 million., A $45 million miss. Lilly shrugged it off. So should you. It was a rounding error with a brand name.
Retail traders will read "dramatic expansion" and buy calls at the open. They will treat a 4% premarket pop as a personality. Then they will sell Friday because the chart "felt extended." You felt nothing. You bought a stock because a CEO used an adjective.
Ricks sees a country where nine in ten eligible people are untreated. You see a ticker. One of you has a plan.
The other has a Robinhood account and a gym membership he's paying for in January.
Photo by on Unsplash
Leave a Comment